Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 3/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900552 | 0.78 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL9899722 | 0.76 | KDM4E (0.39) | NR1H2KMT2A | |
| SCHEMBL1584169 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL21232089 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL934114 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL116328 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL3442167 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL19860426 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL12216558 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL115983 | 0.72 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | HCRTR2, HCRTR1, HTR5A | NR1H2 230/4885MEN1 4080/4885KMT2A 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.